Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jerusalem Pharmaceutical CoXPAE:JPH +113.94%71 ROC (Joel Greenblatt) % is 10.27% as of Jun. 2026, which is 18% below its 10-year median of 12.49. GuruFocus rates XPAE:JPH with a GF Score™ of 71/100 and a GF Value™ of $2.47 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Jerusalem Pharmaceutical Co ranks better than 60.86% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Jerusalem Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 10.27%.
The historical rank and industry rank for Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
XPAE:JPH'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.05 Med: 12.49 Max: 21.14
Current: 18.83
During the past 13 years, Jerusalem Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 21.14%. The lowest was 7.05%. And the median was 12.49%.
XPAE:JPH's ROC (Joel Greenblatt) % is ranked better than 60.86% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.62
vs XPAE:JPH: 18.83
Jerusalem Pharmaceutical Co (XPAE:JPH) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co ROC (Joel Greenblatt) % Chart
XPAE:JPH vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jerusalem Pharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Jerusalem Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 10.27% mean?
Jerusalem Pharmaceutical Co (XPAE:JPH) has a ROC (Joel Greenblatt) % of 10.27% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Jerusalem Pharmaceutical Co and its competitors. This is 18% below median its historical median of 12.49. Over the past decade, Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 7.05 to 21.14. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #384 out of 981 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Jerusalem Pharmaceutical Co's current ROC (Joel Greenblatt) % of 10.27% is 18% below median its 10-year median of 12.49. Over the past 10 years, this metric has ranged from a low of 7.05 to a high of 21.14. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.62. Jerusalem Pharmaceutical Co's value of 10.27% is 11.6% below this industry median. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #384 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #384 out of 981 companies for ROC (Joel Greenblatt) %. This puts Jerusalem Pharmaceutical Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.62. Jerusalem Pharmaceutical Co's value of 10.27% is 11.6% below this benchmark. Historically, Jerusalem Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 7.05 to 21.14 over the past decade. While the company's 10-year median is 12.49 vs. the industry median of 11.62, Jerusalem Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.62, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jerusalem Pharmaceutical Co's current ROC (Joel Greenblatt) % of 10.27% is 11.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Jerusalem Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jerusalem Pharmaceutical Co's current ROC (Joel Greenblatt) % is 10.27%, which is 18% below median its own 10-year median of 12.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.47, compared to a current price of $3.53 — trading 42.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is 10.27%, which is 18% below median its 10-year median of 12.49 and 11.6% below the Drug Manufacturers industry median of 11.62. Jerusalem Pharmaceutical Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current ROC (Joel Greenblatt) % is 10.27% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.53 is trading 42.9% above its estimated GF Value™ of $2.47.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
ROC (Joel Greenblatt) %: 10.27% (18% below median its 10-year median of 12.49)
GF Value™: $2.47 vs. price of $3.53 (42.9% above fair value)
Industry Position: 11.6% below the Drug Manufacturers median (#384 of 981)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
71GF Score
Get the complete analysis for XPAE:JPH
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
